CN114026121A - 治疗多发性骨髓瘤的方法 - Google Patents

治疗多发性骨髓瘤的方法 Download PDF

Info

Publication number
CN114026121A
CN114026121A CN202080024773.7A CN202080024773A CN114026121A CN 114026121 A CN114026121 A CN 114026121A CN 202080024773 A CN202080024773 A CN 202080024773A CN 114026121 A CN114026121 A CN 114026121A
Authority
CN
China
Prior art keywords
antibody
individual
dexamethasone
administered
pomalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024773.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·坎帕纳·詹布拉诺
H·奥德
A·博尼斯特贝
S·汇乐
S·勒盖内克
L·马纳切·阿尔伯里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to CN202510783436.0A priority Critical patent/CN120754030A/zh
Publication of CN114026121A publication Critical patent/CN114026121A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080024773.7A 2019-01-28 2020-01-28 治疗多发性骨髓瘤的方法 Pending CN114026121A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510783436.0A CN120754030A (zh) 2019-01-28 2020-01-28 治疗多发性骨髓瘤的方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962797876P 2019-01-28 2019-01-28
US62/797,876 2019-01-28
US201962847826P 2019-05-14 2019-05-14
US62/847,826 2019-05-14
US201962861954P 2019-06-14 2019-06-14
US62/861,954 2019-06-14
US201962899094P 2019-09-11 2019-09-11
US62/899,094 2019-09-11
US201962931014P 2019-11-05 2019-11-05
US62/931,014 2019-11-05
EP19306554.7 2019-12-03
EP19306554 2019-12-03
US201962943716P 2019-12-04 2019-12-04
US62/943,716 2019-12-04
PCT/US2020/015455 WO2020160020A1 (en) 2019-01-28 2020-01-28 Methods of treating multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510783436.0A Division CN120754030A (zh) 2019-01-28 2020-01-28 治疗多发性骨髓瘤的方法

Publications (1)

Publication Number Publication Date
CN114026121A true CN114026121A (zh) 2022-02-08

Family

ID=69646031

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080024773.7A Pending CN114026121A (zh) 2019-01-28 2020-01-28 治疗多发性骨髓瘤的方法
CN202510783436.0A Pending CN120754030A (zh) 2019-01-28 2020-01-28 治疗多发性骨髓瘤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510783436.0A Pending CN120754030A (zh) 2019-01-28 2020-01-28 治疗多发性骨髓瘤的方法

Country Status (15)

Country Link
US (2) US11939390B2 (https=)
EP (2) EP4588484A3 (https=)
JP (2) JP7712206B2 (https=)
KR (1) KR20210120048A (https=)
CN (2) CN114026121A (https=)
AU (1) AU2020215692A1 (https=)
BR (1) BR112021014699A2 (https=)
CA (1) CA3127928A1 (https=)
CO (1) CO2021011034A2 (https=)
IL (2) IL321343A (https=)
MA (1) MA54860A (https=)
MX (1) MX2021009079A (https=)
SG (1) SG11202108029XA (https=)
TW (2) TWI904081B (https=)
WO (1) WO2020160020A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279065B2 (ja) 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
CN107135654B (zh) 2014-09-12 2021-10-29 加利福尼亚大学董事会 巨胞饮人类抗cd46抗体和靶向癌症疗法
US11939390B2 (en) 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma
US20210171650A1 (en) * 2019-05-14 2021-06-10 Sanofi Methods of administering anti-cd38 antibody
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022006882A (es) * 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
EP4192511A1 (en) * 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugates targeting cd46 and methods of use thereof
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
US20240058464A1 (en) * 2021-01-07 2024-02-22 Fortis Therapeutics, Inc. Combination therapy with for46 for cancer
CN114219787B (zh) * 2021-12-17 2024-08-06 三峡大学 一种初诊多发性骨髓瘤预后分期系统

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104703605A (zh) * 2012-08-09 2015-06-10 细胞基因公司 免疫相关和炎性疾病的治疗
WO2016022589A2 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
CN107033243A (zh) * 2005-03-23 2017-08-11 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
CN107614530A (zh) * 2015-05-13 2018-01-19 莫佛塞斯公司 用于多发性骨髓瘤（mm）的治疗
CN107708734A (zh) * 2015-06-22 2018-02-16 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
WO2018102740A1 (en) * 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
CN108289876A (zh) * 2015-12-01 2018-07-17 肿瘤多肽股份公司 针对癌症的美乐芬剂量方案
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
US11939390B2 (en) 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107033243A (zh) * 2005-03-23 2017-08-11 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
CN104703605A (zh) * 2012-08-09 2015-06-10 细胞基因公司 免疫相关和炎性疾病的治疗
WO2016022589A2 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
CN107614530A (zh) * 2015-05-13 2018-01-19 莫佛塞斯公司 用于多发性骨髓瘤（mm）的治疗
CN107708734A (zh) * 2015-06-22 2018-02-16 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
CN108289876A (zh) * 2015-12-01 2018-07-17 肿瘤多肽股份公司 针对癌症的美乐芬剂量方案
WO2018102740A1 (en) * 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
CN110225756A (zh) * 2016-12-02 2019-09-10 鲁比厄斯治疗法股份有限公司 与用于穿透实体瘤的细胞系统相关的组合物和方法
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
CN110869029A (zh) * 2017-07-09 2020-03-06 拜欧赛特有限公司 组合癌症治疗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN WILLAN: "Multiple myeloma in the very elderly patient: challenges and solutions", 《CLINICAL INTERVENTIONS IN AGING》, 1 April 2016 (2016-04-01), pages 428 *
JOSEPH MIKHAEL: "Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM)", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 36, no. 15, 1 June 2018 (2018-06-01) *
舒冰焰: "CD38通过调控巨噬细胞活化促进肾脏损伤的作用和机制", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, 15 January 2019 (2019-01-15), pages 27 *

Also Published As

Publication number Publication date
EP4588484A2 (en) 2025-07-23
US20200239589A1 (en) 2020-07-30
US11939390B2 (en) 2024-03-26
JP7712206B2 (ja) 2025-07-23
US20240190984A1 (en) 2024-06-13
SG11202108029XA (en) 2021-08-30
IL285110B2 (en) 2025-11-01
KR20210120048A (ko) 2021-10-06
CO2021011034A2 (es) 2021-09-09
IL321343A (en) 2025-08-01
JP2022518060A (ja) 2022-03-11
MA54860A (fr) 2022-05-04
IL285110A (en) 2021-09-30
AU2020215692A1 (en) 2021-09-16
TW202043283A (zh) 2020-12-01
TW202535952A (zh) 2025-09-16
WO2020160020A1 (en) 2020-08-06
CA3127928A1 (en) 2020-08-06
EP4588484A3 (en) 2025-10-15
EP3917961A1 (en) 2021-12-08
MX2021009079A (es) 2022-02-10
BR112021014699A2 (pt) 2021-11-23
CN120754030A (zh) 2025-10-10
IL285110B1 (en) 2025-07-01
JP2025148430A (ja) 2025-10-07
TWI904081B (zh) 2025-11-11

Similar Documents

Publication Publication Date Title
US20240190984A1 (en) Methods of treating multiple myeloma
HK1252272A1 (zh) 使用抗ox40抗体治疗癌症的方法
JP2018513159A (ja) 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
EP3551663A1 (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
CN114080233A (zh) 给予抗cd38抗体以治疗多发性骨髓瘤的方法
CN115052629A (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
JP2025138745A (ja) 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
TW202541838A (zh) 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途
US20250177519A1 (en) Use of isatuximab in combination with other agents for the treatment of multiple myeloma
RU2838203C2 (ru) Способы лечения множественной миеломы
CA3048198A1 (en) Methods of treating multiple myeloma
TWI922320B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
WO2026033458A1 (en) DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
WO2026090536A1 (en) Methods and uses for treating nk cell or t-cell lymphomas or leukemias with anti-cd94 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230307

Address after: new jersey

Applicant after: SANOFI-AVENTIS U.S. LLC

Address before: Paris France

Applicant before: Sai Nuofei

TA01 Transfer of patent application right